Expanded Access Policy

Clinical trials, and the subsequent approval of a therapy, provide the best way to provide long-term access to new therapies to as many patients as possible. Patients interested in an investigational product which has not yet been approved are encouraged to speak with their doctor and, potentially, participate in Savara’s current or future clinical trials. Please find information on our currently ongoing clinical trial by searching for Savara or NCT04544293 at www.clinicaltrials.gov.

Currently, Savara is not offering expanded access in the United States. We encourage you to stay informed regarding our development program, and, as more information and clinical data on the safety and efficacy of molgramostim become available, our policy on expanded access will be reviewed on a regular basis.

For additional information, physicians can contact info@savarapharma.com. Someone will respond within approximately 5 business days.

Patients and families interested in learning general information about expanded access can visit the Expanded Access Navigator.